Comparison of Superior Hypogastric Plexus Block and Peritoneal Bupivacaine in Pain Management

Completed

• Conditions: Superior Hypogastric Plexus Block; Intraperitoneal Bupivacaine
• Interventions: Drug: Intraperitoneal Bupivacaine spray; Drug: Dexketoprofen (KETAVEL 50 mg/2 ml); Drug: Bupivacain

• Registration Number: NCT06954896
• Lead Sponsor: Enes Celik

Brief Summary

Background: Laparoscopic hysterectomy is one of the most frequently performed major surgeries in nonmalignant gynecological diseases. Effective postoperative analgesia is associated with short hospital stays, early mobilization, reduced costs, and patient satisfaction. Intravenous administration of nonsteroidal anti-inflammatory drugs, paracetamol or opioids; epidural catheter placement; peritoneal local anaesthetic administration; and superior hypogastric plexus block (SHPB) are routinely employed methods for postoperative pain management following laparoscopic hysterectomy.

Methods: The study population comprised patients who underwent laparoscopic hysterectomy with or without oophorectomy for benign indications. A total of 94 patients were included in the study. Thirty patients received a superior hypogastric plexus block, thirty received intraperitoneal local anaesthetic spray, and thirty-four received intravenous analgesics.

Conclusion: In the present study, a comparison of postoperative pain management in patients who underwent laparoscopic hysterectomy was conducted.

Detailed Description

In the present study, a comparison of postoperative pain management in patients who underwent laparoscopic hysterectomy was conducted. The findings indicated that the initial postoperative administration of analgesics occurred later in patients who received peritoneal local anesthetics and SHPB compared to the control group. In addition, VAS values at the first and third hours were found to be lower in the peritoneal local anesthetic and SHPB groups than in the control group. Postoperative pain experienced by patients following gynecologic surgery. It has been reported that approximately 75% of patients experience severe pain. Excessive opioid use in postoperative pain management and the potential for additional complications are also possible. One of the alternative methods to reduce postoperative opioid use is intraperitoneal bupivacaine administration.

Study Timeline

• Study Start: 2024-07-01
• Primary Completion: 2024-12-30
• Study Completion: 2025-02-20
• Status Verified: 2025-04
• Study First Submitted: 2025-04-14
• Study First Submitted QC: 2025-04-30
• Last Update Submitted: 2025-04-30
• Study First Posted: 2025-05-02
• Last Update Posted: 2025-05-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 94

Inclusion Criteria

• patients who underwent laparoscopic hysterectomy-with or without oophorectomy-
• ASA physical status I-II patients

Exclusion Criteria

• women with known bupivacaine allergy, anxiety-depressive disorders, fibromyalgia, coagulopathy, eclampsia/preeclampsia, or those who were pregnant were also excluded.
• if they were younger than 18 or older than 65
• underwent epidural catheterisation and/or received additional pain management modalities
• prescribed preoperative antidepressants or gabapentinoids

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
intraperitoneal local anaesthetic spray (Group B)	Intraperitoneal Bupivacaine spray	-
intravenous analgesics (Group C)	Dexketoprofen (KETAVEL 50 mg/2 ml)	-
superior hypogastric plexus block (Group S)	Bupivacain	-

Primary Outcome Measures

Name	Time	Method
VAS (vısual analog scale)	24 HOUR	For patients with no pain, VAS was recorded as 0 (zero), and for those with unbearable pain, VAS was recorded as 10 (ten).

Trial Locations

Locations (1)

Mardin Artuklu University; 🇹🇷 Mardin, Turkey